The Administration &Outreach Core supports SPORE projects and investigators by managing SPORE resources, quality control, and communication and outreach, including fostering interaction among SPORE components and collaborators, other SPORES, the patient and advocate community, and the NCI. This management and support is accomplished through a series of oversight committees and organized administrative and scientific meetings of SPORE investigators, institutional representatives and external advisors. Specific functions of the Core include: To administratively manage and coordinate all SPORE-related research To monitor and manage financial resources To create and prepare documents and reports to ensure compliance with federal regulations and reporting requirements To administer the Developmental Research (pilot project) and Career Development Programs To organize all meetings, seminars, and travel related to Breast Cancer SPORE activities To serve as a point of contact to all VICC fundraising activities focused in breast cancer To support and coordinate all internal and external collaborations To serve as a main point of contact to biotechnology and pharmaceutical companies Carlos L. Arteaga, MD, and Jane Kennedy, MSSW, will serve as co-Directors of the Core. Arteaga reports directly to Jennifer Pietenpol, PhD, Director of VICC, and has input and assistance from the Deputy Director (Daniel Beauchamp, MD) and the Associate Directors for Basic Science (Scott Hiebert, PhD) and Cancer Epidemiology, Prevention &Control (William Blot, PhD). Arteaga provides advice to Dr. Pietenpol on programmatic directions and allocation of VICC resources for research in breast cancer. Since 2006, Ms. Jane Kennedy has served as Manager of Patient Advocacy in the VICC Office of Patient &Community Education (OPACE). Ms. Kennedy's role includes recruiting, training and coordinating the survivors and caregivers who contribute to and support the Research Advocacy Program of VICC, including the Breast SPORE.
The Administration &Outreach Core supports SPORE projects and investigators by managing SPORE resources and finances, facilitating communications, coordinating outreach activities, fostering interactions (among SPORE components and collaborators, other SPOREs, the community and the NCI), and administering programmatic initiatives.
|Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2016) A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res :|
|Lee, Taekyu; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. FEBS Lett :|
|Harris, Leonard A; Frick, Peter L; Garbett, Shawn P et al. (2016) An unbiased metric of antiproliferative drug effect in vitro. Nat Methods 13:497-500|
|Zhao, Min; Kim, Pora; Mitra, Ramkrishna et al. (2016) TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res 44:D1023-31|
|Bhola, Neil E; Jansen, Valerie M; Koch, James P et al. (2016) Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res 76:440-52|
|Degnim, Amy C; Dupont, William D; Radisky, Derek C et al. (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122:2971-8|
|Zhao, Junfei; Cheng, Feixiong; Wang, Yuanyuan et al. (2016) Systematic Prioritization of Druggable Mutations in âˆ¼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. Mol Cell Proteomics 15:642-56|
|Pelz, Nicholas F; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. J Med Chem 59:2054-66|
|Jansen, Valerie M; Mayer, Ingrid A; Arteaga, Carlos L (2016) Is There a Future for AKT Inhibitors in the Treatment of Cancer? Clin Cancer Res 22:2599-601|
|Hassanein, Mohamed; Hight, Matthew R; Buck, Jason R et al. (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18:18-23|
Showing the most recent 10 out of 304 publications